Intensivmedizinische Aspekte der Antibiotikatherapie

  • Sebastian Lemmen
  • Karl Lewalter
  • Wolfgang Krüger
Living reference work entry

Latest version View entry history

Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Während viele Maßnahmen in der Intensivmedizin supportiv sind, ermöglichen Antibiotika eine kausale Therapie. Die Auswahl erfolgt jedoch meist vor dem mikrobiologischen Nachweis, sodass sich die kalkulierte Therapie an den wahrscheinlichsten Erregern orientieren muss. Deutliche regionale Unterschiede bedingen, dass für viele Infektionen zwar ein typisches, aber nicht allgemein gültiges Erregerspektrum angegeben werden kann.

Literatur

  1. 1.
    Beaucaire C (2000) Does once-daily dosing prevent nephrotoxicity in all Aminoglykosides equally? Clin Microbiol Infect 6:357–362CrossRefPubMedGoogle Scholar
  2. 2.
    Blot SI, Pea F, Lipman J (2014) The effect of pathophysiology on pharmacokinetics in the critically ill patient – concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014 Nov 20:77:3–11Google Scholar
  3. 3.
    Brunkhorst FM, Oppert M, Marx G et al (2012) Effect of empirical treatment with Moxifloxacin and Meropenem vs Meropenem on sepsis-related organ dysfunction in patientes with severe sepsis. JAMA 307:2390–2399CrossRefPubMedGoogle Scholar
  4. 4.
    Cunha BA (1999) Fever in the intensive care unit. Intensive Care Med 25:648–651CrossRefPubMedGoogle Scholar
  5. 5.
    Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections. Chest 115:462–474CrossRefPubMedGoogle Scholar
  6. 6.
    Krueger WA, Ruckdeschel G, Unertl K (1997) Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate. Antimicrob Agents Chemother 41:1725–1730PubMedPubMedCentralGoogle Scholar
  7. 7.
    Krueger WA, Ruckdeschel G, Unertl K (1999) Elimination of fecal Enterobacteriaceae by intravenous ciprofloxacin is not inhibited by concomitant sucralfate – a microbiological and pharmacokinetic study in patients. Infection 27:335–340CrossRefPubMedGoogle Scholar
  8. 8.
    Krueger WA, Bulitta J, Kinzig-Schippers M et al (2005) Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 49:1881–1889CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596CrossRefPubMedGoogle Scholar
  10. 10.
    Lemmen SW, Engels I, Daschner FD (1997) Serum bactericidal activity of ceftazidime administered as continuous infusion of 3 g over 24 h vs. intermittent bolus infusion of 2 g against Pseudomonas aeruginosa in healthy volunteers. J Antimicrob Chemother 39:841–842CrossRefPubMedGoogle Scholar
  11. 11.
    Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L (2004) Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328:668CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J (2007) Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 30:11–18CrossRefPubMedGoogle Scholar
  13. 13.
    Roberts JA, Abdul-Aziz MH, Lipman J et al (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14:498–509CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Weinstein RA (1986) Endemic emergence of resistance of cephalosporin-resistant enterobacter: relation to prior therapy. Infect Control 7:120–123CrossRefPubMedGoogle Scholar

Copyright information

© © Springer-Verlag GmbH Deutschland 2018

Authors and Affiliations

  • Sebastian Lemmen
    • 1
  • Karl Lewalter
    • 1
  • Wolfgang Krüger
    • 2
  1. 1.Uniklinik RWTH Aachen, Zentralbereich für Krankenhaushygiene und InfektiologieAachenDeutschland
  2. 2.Klinikum Konstanz, Klinik für Anaesthesiologie und Operative IntensivmedizinKonstanzDeutschland

Section editors and affiliations

  • Rolf Rossaint
    • 1
  1. 1.Klinik für operative Intensivmedizin und Intermediate CareUniversitätsklinikum AachenAachenDeutschland

Personalised recommendations